Urania Dafni

15.4k total citations · 2 hit papers
157 papers, 7.5k citations indexed

About

Urania Dafni is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Urania Dafni has authored 157 papers receiving a total of 7.5k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Oncology, 47 papers in Pulmonary and Respiratory Medicine and 19 papers in Surgery. Recurrent topics in Urania Dafni's work include Lung Cancer Treatments and Mutations (29 papers), Lung Cancer Diagnosis and Treatment (19 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Urania Dafni is often cited by papers focused on Lung Cancer Treatments and Mutations (29 papers), Lung Cancer Diagnosis and Treatment (19 papers) and Cancer Immunotherapy and Biomarkers (18 papers). Urania Dafni collaborates with scholars based in Greece, United States and Switzerland. Urania Dafni's co-authors include Haralampos Μ. Moutsopoulos, Fotini N. Skopouli, Martine Piccart, Elisabeth G.E. de Vries, Zoi Tsourti, Christoph Zielinski, Nathan I. Cherny, George Fountzilas, John P. A. Ioannidis and Solange Peters and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of Clinical Oncology.

In The Last Decade

Urania Dafni

152 papers receiving 7.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

2015 533 citations Urania Dafni, Martine Piccart et al. Annals of Oncology profile →
ESMO-Magnitude of Clinical Benefit Scale version 1.1

2017 369 citations Urania Dafni, Martine Piccart et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Urania Dafni Greece	48	3.1k	1.7k	1.1k	945	934	157	7.5k
Jonathan Sussman United States	49	4.0k 1.3×	1.2k 0.7×	1.5k 1.3×	383 0.4×	815 0.9×	269	8.0k
Clifton O. Bingham United States	60	2.0k 0.7×	713 0.4×	1.1k 1.0×	883 0.9×	1.3k 1.3×	275	11.4k
Martin Krapcho United States	10	3.6k 1.2×	2.0k 1.2×	1.3k 1.1×	252 0.3×	1.3k 1.4×	14	8.2k
Matthew J. Maurer United States	61	5.0k 1.6×	1.4k 0.8×	1.0k 0.9×	875 0.9×	4.6k 5.0×	481	14.3k
Matt Hayat United States	5	3.3k 1.1×	1.9k 1.1×	1.2k 1.1×	233 0.2×	1.3k 1.4×	6	7.9k
Marie‐Josèphe Horner United States	11	3.6k 1.2×	1.9k 1.2×	1.3k 1.2×	246 0.3×	1.3k 1.4×	26	8.2k
Alexander Katalinic Germany	56	3.9k 1.2×	1.3k 0.8×	1.4k 1.3×	228 0.2×	1.1k 1.2×	381	9.0k
Milton P. Eisner United States	5	3.6k 1.1×	1.9k 1.2×	1.3k 1.2×	235 0.2×	1.3k 1.4×	10	8.1k
B. Miller United States	5	3.6k 1.2×	1.9k 1.2×	1.2k 1.1×	239 0.3×	1.3k 1.4×	6	8.2k
Harmon J. Eyre United States	39	4.2k 1.3×	1.9k 1.2×	1.0k 0.9×	413 0.4×	1.1k 1.2×	95	8.6k

Countries citing papers authored by Urania Dafni

Since Specialization

Citations

This map shows the geographic impact of Urania Dafni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Urania Dafni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Urania Dafni more than expected).

Fields of papers citing papers by Urania Dafni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Urania Dafni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Urania Dafni. The network helps show where Urania Dafni may publish in the future.

Co-authorship network of co-authors of Urania Dafni

This figure shows the co-authorship network connecting the top 25 collaborators of Urania Dafni. A scholar is included among the top collaborators of Urania Dafni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Urania Dafni. Urania Dafni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schil, Paul E. Van, M. Pérol, Kersti Oselin, et al.. (2025). 175TiP: ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC. Journal of Thoracic Oncology. 20(3). S118–S119. 1 indexed citations

Hackshaw, Allan, Otto Fajardo, Urania Dafni, et al.. (2024). Characteristics and Survival Outcomes of Patients With Metastatic RET Fusion–Positive Solid Tumors Receiving Non-RET Inhibitor Standards of Care in a Real-World Setting. JCO Precision Oncology. 8(8). e2300334–e2300334.

Kinj, Rémy, Olivier Gaide, Wendy Jeanneret‐Sozzi, et al.. (2024). Randomized phase II selection trial of FLASH and conventional radiotherapy for patients with localized cutaneous squamous cell carcinoma or basal cell carcinoma: A study protocol. Clinical and Translational Radiation Oncology. 45. 100743–100743. 19 indexed citations

Soo, Ross A., Urania Dafni, Ji‐Youn Han, et al.. (2024). ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial. Clinical Cancer Research. 30(22). 5180–5191. 1 indexed citations

Marta, Guilherme Nader, Véronique Debien, Daniel Eiger, et al.. (2022). Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy—a sub-analysis of the ALTTO study. British Journal of Cancer. 127(10). 1799–1807. 1 indexed citations

Meylan, Sylvain, Urania Dafni, Frédéric Lamoth, et al.. (2021). SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study. BMJ Open. 11(7). e049232–e049232. 8 indexed citations

Dafni, Urania, et al.. (2019). Breast Cancer Statistics in the European Union: Incidence and Survival across European Countries. Breast Care. 14(6). 344–353. 137 indexed citations

Dziadziuszko, Rafał, Egbert F. Smit, Urania Dafni, et al.. (2019). Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). Journal of Thoracic Oncology. 14(6). 1086–1094. 107 indexed citations

Filipits, Martin, Urania Dafni, Michael Gnant, et al.. (2018). Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. Clinical Cancer Research. 24(13). 3079–3086. 15 indexed citations

10.

Loi, Sherene, Urania Dafni, Dimitris Karlis, et al.. (2016). Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab. JAMA Oncology. 2(8). 1040–1040. 65 indexed citations

11.

Pectasides, Eirini, Clarence T. Sasaki, Panteleimon Kountourakis, et al.. (2010). Nuclear Localization of Signal Transducer and Activator of Transcription 3 in Head and Neck Squamous Cell Carcinoma Is Associated with a Better Prognosis. Clinical Cancer Research. 16(8). 2427–2434. 58 indexed citations

12.

Briasoulis, Evangelos, Periklis Pappas, C. Puozzo, et al.. (2009). Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer. Clinical Cancer Research. 15(20). 6454–6461. 77 indexed citations

13.

Koutras, Αngelos, Konstantine T. Kalogeras, Meletios Α. Dimopoulos, et al.. (2008). Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study. British Journal of Cancer. 99(11). 1775–1785. 53 indexed citations

14.

Fountzilas, George, Pavlos Papakostas, Urania Dafni, et al.. (2006). Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non–nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group. Annals of Oncology. 17(10). 1560–1567. 22 indexed citations

15.

Gogas, Helen, J. Ioannovich, Urania Dafni, et al.. (2006). Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon. New England Journal of Medicine. 354(7). 709–718. 428 indexed citations

16.

Dimopoulou, Ioanna, Stylianos Tsagarakis, Evangelia Douka, et al.. (2004). The low-dose corticotropin stimulation test in acute traumatic and non-traumatic brain injury: incidence of hypo-responsiveness and relationship to outcome. Intensive Care Medicine. 30(6). 1216–1219. 37 indexed citations

17.

Brokalaki, Hero, et al.. (2001). Job‐related stress among nursing personnel in Greek dialysis units. EDTNA-ERCA Journal. 27(4). 181–186. 27 indexed citations

18.

Madianos, Michael G., et al.. (2001). Psychiatric Disorders in Burn Patients: A Follow-Up Study. Psychotherapy and Psychosomatics. 70(1). 30–37. 95 indexed citations

19.

DeGruttola, Victor, Nicholas Lange, & Urania Dafni. (1991). Modeling the Progression of HIV Infection. Journal of the American Statistical Association. 86(415). 569–569. 25 indexed citations

20.

DeGruttola, Victor, Nicholas Lange, & Urania Dafni. (1991). Modeling the Progression of HIV Infection. Journal of the American Statistical Association. 86(415). 569–577. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact